Edition:
India

Pluristem Therapeutics Inc (PSTI.OQ)

PSTI.OQ on NASDAQ Stock Exchange Capital Market

1.28USD
20 Jul 2018
Change (% chg)

$-0.02 (-1.54%)
Prev Close
$1.30
Open
$1.28
Day's High
$1.28
Day's Low
$1.28
Volume
3,000
Avg. Vol
74,125
52-wk High
$2.12
52-wk Low
$1.06

Chart for

About

Pluristem Therapeutics Inc. is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The Company's lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome. Its... (more)

Overall

Beta: 0.11
Market Cap(Mil.): $145.24
Shares Outstanding(Mil.): 97.47
Dividend: --
Yield (%): --

Financials

Israel's Pluristem sees positive results from leg pain study

TEL AVIV Israel's Pluristem Therapeutics Inc, a developer of placenta-based stem cell products, said on Tuesday it had positive results from a mid-stage study of its therapy to treat leg pain known as intermittent claudication (IC).

13 Jun 2018

Israel's Pluristem sees positive results from leg pain study

TEL AVIV, June 12 Israel's Pluristem Therapeutics Inc, a developer of placenta-based stem cell products, said on Tuesday it had positive results from a mid-stage study of its therapy to treat leg pain known as intermittent claudication (IC).

12 Jun 2018

FDA clears Pluristem radiation treatment for emergency use

HAIFA, Israel Pluristem Therapeutics Inc, a developer of placenta-based stem cell products, said the U.S. Food and Drug Administration has cleared the emergency use of its therapy to treat acute radiation exposure in a nuclear event.

30 Apr 2018

FDA clears Pluristem radiation treatment for emergency use

HAIFA, Israel, April 30 Pluristem Therapeutics Inc, a developer of placenta-based stem cell products, said the U.S. Food and Drug Administration has cleared the emergency use of its therapy to treat acute radiation exposure in a nuclear event.

30 Apr 2018

BRIEF-U.S. FDA Clears Pluristem’S Phase III Study In Treatment Of Muscle Injury Following Hip Fracture Surgery

* U.S. FDA CLEARS PLURISTEM’S PHASE III STUDY IN TREATMENT OF MUSCLE INJURY FOLLOWING HIP FRACTURE SURGERY

25 Apr 2018

Earnings vs. Estimates